Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane

• Status: Completed
• Trial end date: 2015-06-01

Summary

The purpose of the study is to determine whether ODSH (2-0,3-0 desulfated heparin), a low anticoagulant heparin derivate with preserved anti-inflammatory and anti-neoplastic characteristics is efficacious in patients with metastatic pancreatic cancer with gemcitabine and nab-paclitaxel ( Abraxane) as first line therapy.

• Phase: Phase 2

Details

• Lead Sponsor: Cantex Pharmaceuticals; Chimerix
• Collaborator: Translational Drug Development
• Treatments: Albumin-Bound Paclitaxel; Calcium heparin; Gemcitabine; Heparin; Paclitaxel